Sanofi CEO Christopher Viehbacher discusses his company's $20 billion acquisition of Genzyme and other opportunities he sees in the pharmaceutical market.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT